Last edition
News about "Nilesh Gupta"
Lupin Receives US FDA EIR for Ankleshwar Manufacturing Facility
Lupin has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Ankleshwar facility following the successful closure of a product-specific pre-approval inspection conducted in March 2026.
Nilesh Gupta | 28/05/2026 | By News Bureau
Lupin and Zydus Partner to Co-Market Semaglutide Injection in India
Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.
Nilesh Gupta | 18/03/2026 | By News Bureau | 211
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
Nilesh Gupta | 30/12/2025 | By News Bureau | 176
Lupin Receives EIR from US FDA for its Aurangabad (CSN) Facility
Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its Aurangabad (CSN) facility, marking the successful closure of a product-specific Pre-Approval Inspection conducted between September 1 and September 5, 2025.
Nilesh Gupta | 14/11/2025 | By Dineshwori | 204
Lupin Receives EIR from US FDA for its Pithampur Unit-3 Facility
Following an inspection in July 2025, Lupin received the USFDA’s Establishment Inspection Report (EIR) for its Pithampur Unit-3 facility.
Nilesh Gupta | 06/11/2025 | By Dineshwori | 317
Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
Lupin’s Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
Nilesh Gupta | 14/08/2023 | By Sudeep Soparkar | 904
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy